AbbVie Inc. (ABBV)
$
222.44
-0.82 (-0.37%)
Key metrics
Financial statements
Free cash flow per share
7.7578
Market cap
393.1 Billion
Price to sales ratio
6.4280
Debt to equity
-26.0193
Current ratio
0.7245
Income quality
3.2622
Average inventory
4.9 Billion
ROE
8.8042
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide, offering a diverse portfolio of therapies. The company reported a substantial revenue of $61,160,000,000.00 reflecting its strong market presence. Among its key offerings are HUMIRA, an injection therapy for autoimmune and intestinal Behçet's diseases, and SKYRIZI, which treats moderate to severe plaque psoriasis in adults. Additionally, RINVOQ serves as a JAK inhibitor for moderate to severe active rheumatoid arthritis, while IMBRUVICA and VENCLEXTA are utilized for chronic lymphocytic leukemia and small lymphocytic lymphoma treatment. MAVYRET targets chronic HCV genotype 1-6 infections, and the company also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency. Furthermore, Synthroid is used for hypothyroidism, while Linzess/Constella addresses irritable bowel syndrome with constipation. Lupron targets advanced prostate cancer and other conditions, and Botox therapeutic is part of their offerings. AbbVie continues its innovation with ORILISSA, a treatment for endometriosis pain, and Duopa and Duodopa, which help manage Parkinson's disease. The company’s ophthalmic products include Lumigan/Ganfort for elevated intraocular pressure and Restasis, which boosts tear production. The gross profit ratio is 0.84 reflecting the efficiency of the company's production and sales operations. The earnings per share (EPS) is reported at $2.38 indicating the company's profitability on a per-share basis. Moreover, the net total of other income and expenses is -$14,617,000,000.00 reflecting non-core financial activities, while the weighted average number of shares outstanding is 1,790,678,000.00 highlighting the company's shareholder base. In the financial market, the stock is reasonably priced at $222.47 appealing to a broad range of investors. AbbVie has a high average trading volume of 6,495,475.00 indicating strong liquidity, and boasts a large market capitalization of $393,136,007,200.00 establishing it as a dominant player. It is a key player in the Drug Manufacturers - General industry, contributing significantly to the overall market landscape, and belongs to the Healthcare sector, driving innovation and growth. This robust combination of research, product diversity, and solid financial metrics underpins AbbVie's position as a leader in the pharmaceutical market.
Is AbbVie Inc. (ABBV) a good investment?
Investing in AbbVie Inc. (ABBV) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C-, with a Bullish outlook. Always conduct your own research before investing.
What is AbbVie Inc. (ABBV)'s stock forecast?
Analysts predict AbbVie Inc. stock to fluctuate between $164.39 (low) and $244.81 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is AbbVie Inc.'s market capitalization?
As of 2026-02-10, AbbVie Inc.'s market cap is $393,136,007,200, based on 1,767,380,000 outstanding shares.
How does AbbVie Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., AbbVie Inc. has a Lower Market-Cap, indicating a difference in performance.
Does AbbVie Inc. pay dividends?
AbbVie Inc. pays dividends. The current dividend yield is 3.10%, with a payout of $1.73 per share.
How can I buy AbbVie Inc. (ABBV) stock?
To buy AbbVie Inc. (ABBV) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ABBV. Place an order (Market, Limit, etc.).
What is the best time to invest in AbbVie Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did AbbVie Inc. perform in the last earnings report?
Revenue: $61,160,000,000 | EPS: $2.38 | Growth: -0.83%.
Where can I find AbbVie Inc.'s investor relations reports?
Visit https://www.abbvie.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for AbbVie Inc.?
You can explore historical data from here
What is the all-time high and low for AbbVie Inc. stock?
All-time high: $244.81 (2025-10-01) | All-time low: $105.56 (2021-09-20).
What are the key trends affecting AbbVie Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
seekingalpha.com
Dividend Kings remain broadly overvalued, with only a handful approaching fair price despite elevated yields. Three Dividend Kings—Canadian Utilities, Fortis, and Hormel—currently meet the dogcatcher 'ideal' but face dividend safety concerns due to negative free cash flow margins. Analyst projections estimate 14.16% to 27.77% net gains for top-yielding Dividend Kings by February 2027, with ABBV and NWN ranking in the top 20 across yield, target, and returns.
zacks.com
ABBV sees 2026 revenues rising to $67B as Rinvoq and Skyrizi drive growth, with neuroscience gains offsetting Humira erosion and oncology headwinds.
marketbeat.com
When the price of a high-quality stock such as AbbVie NYSE: ABBV declines after a report revealing growth, outperformance, and better-than-expected guidance, it's almost always a good time to buy.
seekingalpha.com
AbbVie delivered a resilient Q4 with 10% YoY revenue growth and strong immunology performance, despite a post-earnings stock selloff. Their adjusted EPS grew 25% YoY, beating estimates, while operating margin expanded 360 bps, demonstrating improved efficiency. Forward guidance for FY2026 EPS of $14.37-$14.57 implies 13% growth, exceeding analyst expectations by $0.25 per share.
seekingalpha.com
AbbVie has significantly outperformed prior immunology sales projections, with Skyrizi and Rinvoq now expected to reach $38 billion by 2030. ABBV's oncology and neuroscience pipelines have expanded via ImmunoGen and Cerevel acquisitions, supporting robust growth beyond immunology. Sales and EPS growth through 2030 are forecast to outpace most peers, with a projected 6.6% sales CAGR and 7.7% EPS CAGR.
seekingalpha.com
AbbVie Inc. has delivered strong long-term returns and maintains a >3% dividend yield, but recent Q4 earnings and guidance have tempered my near-term enthusiasm. ABBV's immunology and neuroscience divisions are thriving, with Skyrizi and Rinvoq driving robust growth, yet competition and market saturation present future risks. Management projects high single-digit revenue CAGR through the decade, but detailed 2026 guidance limits upside surprise and leaves little room for error.
seekingalpha.com
AbbVie Inc. faces investor skepticism on growth durability beyond Immunology, despite strong SKYRIZI and RINVOQ performance offsetting HUMIRA's decline. ABBV's Q4 2025 saw 18% Immunology growth and 10% total revenue growth, but Oncology and Aesthetics portfolios declined, highlighting diversification challenges. 2026 adjusted EPS guidance of $14.37–$14.57 excludes unpredictable IPR&D and milestone costs, raising concerns about reliance on M&A for future growth.
zacks.com
ABBV beats Q4 earnings and revenue estimates, but shares slip as Rinvoq and oncology sales miss expectations despite strong 2026 EPS guidance.
seekingalpha.com
AbbVie Inc. (ABBV) Q4 2025 Earnings Call Transcript
See all news
